STA Pharmaceutical Co., a WuXi AppTec subsidiary focused on small-molecule pharmaceutical development and manufacturing, and Regulus Therapeutics, a San Diego, California-headquartered biopharmaceutical company focused on microRNA-targeting drugs, have entered into an oligonucleotide synthesis collaboration agreement for research and mid-scale non-GMP/cGMP manufacturing.

Under the agreement, STA will become a new strategic development and manufacturing partner for Regulus’ preclinical and clinical programs of microRNA-targeting drugs used to treat a range of diseases. Regulus will provide STA with technical knowledge and training in the field of oligonucleotide scale-up.

STA recently established oligonucleotide research and development labs at its facilities in San Diego, California and Changzhou, China. The oligonucleotide GMP manufacturing facility at Changzhou will become operational later in 2018.

Source: STA Pharmaceutical